Background
==========

Colorectal carcinoma (CRC) is the third most common cancer and the fourth most common cause of cancer mortality worldwide \[[@b1-medscimonit-24-1080]\]. From a genetic perspective, CRC is one of the best understood neoplasms, but it is still the second most common cause of cancer-related death. The diagnosis and treatment of CRC have been significantly improved in recent years, leading to a substantial reduction in cancer-related mortality \[[@b2-medscimonit-24-1080]\]. However, CRC is still a major worldwide public health problem. Several biomarkers have been shown to exhibit tumor suppressor functions in CRC \[[@b3-medscimonit-24-1080]\].

FBXO32 (F-box protein 32) is a member of the F-box protein family, which constitutes 1 of the 4 subunits of the ubiquitin protein ligase complex involved in muscle atrophy \[[@b4-medscimonit-24-1080],[@b5-medscimonit-24-1080]\]. FBXO32 is very strongly induced in many catabolic states and plays an important role in the generation of muscle atrophy \[[@b6-medscimonit-24-1080]\]. Moreover, reports have shown that FBXO32 contributes to 3-deazaneplanocin A-induced apoptosis in breast cancer cells, and thus, it may also regulate cell survival \[[@b7-medscimonit-24-1080]\]. Recent findings have demonstrated that *fbxo32* may regulate cell survival and act as a potential tumor suppressor \[[@b8-medscimonit-24-1080]\]. A previous study identified *fbxo32* as a transforming growth factor-β (TGF-β)/Smad4 signalling pathway target gene, and it was transcriptionally silenced by epigenetic mechanisms in some types of carcinomas \[[@b8-medscimonit-24-1080]\]. The TGF-β signalling pathway plays a key role in the regulation of cell proliferation, migration, and survival, which affect multiple biological processes, including carcinogenesis, fibrosis and wound healing \[[@b9-medscimonit-24-1080]\]. As a previous study showed that *fbxo32* has a key role in regulating apoptosis in ovarian cancer \[[@b10-medscimonit-24-1080]\], we investigated whether *fbxo32* induces apoptosis in CRC. However, few studies have examined the consequences of TGF-β signalling in CRC. Recently, we identified a TGF-β/Smad4 target *fbxo32,* which was expressed in normal colorectal cells but was epigenetically silenced in CRC cells showing dysregulated TGF-β signalling. These and several other results have suggested that dysregulation of a signalling pathway may cause epigenetic silencing of downstream targets \[[@b11-medscimonit-24-1080]\]. *Smad4*, which is a tumor suppressor gene, is a central mediator in the signalling pathways of the TGF-β superfamily. *Smad4* acts as a common partner of activated Smads to help execute their function by interacting with nuclear-pore complexes. Inactivation of the *smad4* gene through mutation occurs frequently in pancreatic and CRCs and is associated with malignant progression of cancers \[[@b12-medscimonit-24-1080]\].

In this study, we focused on the FBXO32 expression in CRC and established the relationship between FBXO32 expression and clinicopathologic features. We also investigated the role of *fbxo32* in the regulation of CRC progression *in vitro* and evaluated the prognostic role of *fbxo32* in CRC patients.

Material and Methods
====================

Clinical and tissue samples
---------------------------

We chose primary tumor samples (n=122) and matched corresponding normal mucosa (n=43) from patients between July 2006 and June 2017 in the Linyi Peoples' Hospital and Qilu Hospital of Shandong University ([Table 1](#t1-medscimonit-24-1080){ref-type="table"}**)**. Follow-up was conducted by telephone visit. The patients who died of diseases not directly related to their CRC or due to unexpected events were excluded from this study. The pathological diagnosis was conducted before surgery and validated after surgery. CRC samples for use in scientific research were collected with permission from the patients. All patients provided written informed consent, and our study was approved by the institutional review boards of all institutions involved.

Materials
---------

RpMI-1640, DMEM (high glucose), McCoy's 5A and fetal bovine serum (FBS) were obtained from Invitrogen (Gibco, USA). RNeasy RNA kits were purchased from TIANGEN Biotechnology Co., Ltd. (Beijing, China). The neutralizing anti-human FBXO32 monoclonal antibody and anti-GAPDH antibody were from Abcam, Inc. (CA, USA). An immunohistochemistry (IHC) kit was obtained from Maixin Biological Co. (Fuzhou, China).

Immunohistochemistry
--------------------

FBXO32 and SMAD4 were stained with the two-step staining method of EnVision™, and the major steps are described as follows. Tissue sections were dewaxed in xylene, rehydrated in alcohol, and immersed in 3% hydrogen peroxide for 10 min to suppress endogenous peroxidase activity. Antigen retrieval was conducted by heating each section at 100°C for 30 min in 0.01 mol/l sodium citrate buffer (pH 6.0). After three 5-min rinses in phosphate-buffered saline (PBS), the sections were incubated for 1 h at room temperature with a mouse polyclonal anti-FBXO32 antibody (Epitomics, UK) diluted 1: 50 in PBS, and the bound antibodies were detected with a streptavidin-biotin-peroxidase system (Dako, USA) and 3,3′-diaminobenzidine substrate-chromogen solution (Dako, USA). The slides were counterstained with hematoxylin and inspected by an experienced pathologist. The staining area was scored as 0 (0%), 1 (1--25%), 2 (26--50%), 3 (51--75%), or 4 (76--100%) based on the percentage of positively stained cells \[[@b13-medscimonit-24-1080]\]. The images were captured with an inverted Nikon Eclipse TE2000-S microscope (Tokyo, Japan) with 200× magnification, and then, the presence of green fluorescence indicative of a-SMA was qualitatively analyzed by 2 investigators blinded to the study. The degree and intensity of staining were independently assessed by 2 pathologists in a blinded manner.

Cell Culture
------------

We purchased the human CRC cell lines HT-29, HCT-116 and Caco-2 from the Institute of Cell and Biochemistry, Chinese Academy of Sciences (Shanghai, China), and the normal human cell line NCM-460 from the American Type Culture Collection (ATCC). We plated HCT-116 and NCM-460 cells in culture plates with McCoy's 5A medium (Gibco, USA), which was supplemented by 10% FBS (Gibco, USA) and penicillin/streptomycin (Invitrogen) at 100 U/ml; Caco-2 was propagated DMEM (high glucose) medium (Gibco, USA) containing 20% FBS; and HT-29 was cultured in RPMI-1640 medium (Gibco, USA) with 10% FBS. All cells were incubated in a humidified incubator at 37°C in 5% CO~2~.

Quantitative real-time PCR (qRT-PCR) assay
------------------------------------------

QRT-PCR assays were performed to detect the expression of*fbxo32*, *smad4*, *pai-1,* and *vegf* mRNA in NCM460, HCT116, HT-29, and Caco-2 cells. Total RNA was separated from cells by the centrifugal column method (TIANGEN Biotech, Beijing, China), reverse transcribed into cDNA using the Superscript first strand synthesis kit (Invitrogen) in accordance with the manufacturer's protocol, and amplified by qRT-PCR using a Mini-Opticon real-time PCR detection system (ABI, CA, USA) in SYBR Green II master mix (GeneCopoeia, Guangzhou, China) as described by the manufacturer's instructions. All data were analyzed by Opticon Monitor software (ABI; 7500). All primer sequences are listed in [Table 2](#t2-medscimonit-24-1080){ref-type="table"}.

The PCR conditions were as follows: 10 min at 95°C, 40 cycles of 95°C for 10 s, 60°C for 20 s, and 15 s at 72°C. The mRNA level of each sample normalized to the level of GAPDH mRNA and is presented as the unit values of 2\^\[Ct~(~*~gapdh~*~)~--Ct~(~*~fbxo32~*~)~\]. The amplified PCR products were analyzed by agarose gel electrophoresis with a 1.5% gel. Each experiment was performed in triplicate.

Western blot analysis
---------------------

Cells were harvested and lysed using immunoprecipitation assay buffer containing protease inhibitors and phosphatase inhibitors for 30 min on ice. Protein concentrations of the cell lysates were determined by the BCA method (Beyotime). The proteins were placed on 10% gradient gels and then separated by SDS-PAGE (Bio-Rad, Hercules, CA). Resolved proteins were electrophoretically transferred onto PVDF membranes (Invitrogen) and then blocked for 1 h at room temperature with 5% non-fat dry milk in TBST containing 0.1% Tween 20. The membranes were probed with rabbit anti-GAPDH (mAb) (1: 1000) or rabbit anti-FBXO32 monoclonal antibody (mAb) (1: 1000) overnight at 4°C. Then, they were washed with 1×TBST and incubated in secondary antibodies diluted 1: 2000 that were conjugated to horseradish peroxidase (Santa Cruz, USA) for 2 h at room temperature with enhanced chemiluminescence reagents to detect the proteins (Boster, Wuhan, China). The membrane protein bands were imaged using X-film (Kodak Co.) and scanned. All Western blots were performed 3 times at least.

Statistical analysis
--------------------

The SPSS17.0 statistical software was used analyze experimental data. For statistical analysis, Fisher's exact test was conducted for any 2×2 tables, Pearson χ^2^ test was conducted for non-2×2 tables, and the chi-square trend test was conducted for ordinal date. Kaplan-Meier method and log-rank test to determine patient survival*, p*\<0.05 was defined as statistically significant.

Results
=======

FBXO32 and SMAD4 expression in CRC and normal colorectal tissues
----------------------------------------------------------------

FBXO32 and SMAD4 expression was low in CRC samples but high in normal colorectal tissues. Heterogeneous FBXO32 immunostaining was observed in 43 samples of normal tissues and 122 specimens of CRC, as shown in [Figure 1](#f1-medscimonit-24-1080){ref-type="fig"}.

Although weak staining was observed in several stromal cells, scattered areas of weak heterogeneous FBXO32 immunostaining in epithelial cell membranes were found in 18/43 (41.8%) normal tissue specimens, while 25/43 (58.2%) tissues were positive for FBXO32 (score 1--3). For FBXO32-positive primary CRC samples, heterogeneous weak-moderate (score 1--2), and strong staining (score 3) was respectively found in 86/122 (70.5%) and 36/122 (29.5%) samples, and SMAD4 strong staining in normal tissue 20/43 (46.5%), but only strong staining in normal tissue 41/122 (33.6%).

Association of FBXO32 and Smad4 with clinicopathological characteristics of CRC
-------------------------------------------------------------------------------

The relationship between FBXO32 and SMAD4 with pathological features of cancer patients is shown in [Table 3](#t3-medscimonit-24-1080){ref-type="table"}. High expression of FBXO32 tended to be related to the tumor stage (p=0.016) and lymphatic vessel invasion (p=0.031). The incidence of positive FBXO32 expression was increased based on histologic grade (p=0.012). However, SMAD4 expression was only related to tumor grade (p=0.005) and lymphatic vessel invasion (p=0.006).

*fbxo32*, *smad4*, *vegf*, and *pai-1* mRNA and protein levels in primary CRC cell lines
----------------------------------------------------------------------------------------

We examined mRNA expression in CRC cell lines and normal colorectal cells using qRT-PCR. The results showed a statistically higher elevation of *fbxo32* mRNA expression in non-tumor cell than tumor cells (*p*\<0.01, [Figure 2A](#f2-medscimonit-24-1080){ref-type="fig"}). *Smad4* and *pai-1* mRNA levels were also higher in non-tumor cells than in tumor cells (*p*\<0.01, *p*\<0.05, [Figure 2B, 2C](#f2-medscimonit-24-1080){ref-type="fig"}). However, *vegf* mRNA expression showed the opposite pattern, notably in HCT-116 and Caco-2 cells (*p*\<0.05, [Figure 2D](#f2-medscimonit-24-1080){ref-type="fig"}). To investigate whether *fbxo32* was elevated at the protein level, we assessed the CRC cell lines were by Western blot. We found that FBXO32 protein levels in tumor cells were much lower than those in non-tumor cells, as shown in ([Figure 3](#f3-medscimonit-24-1080){ref-type="fig"}), which confirmed the qRT-PCR results. The HT-29, HCT-116 and Caco-2 cell lines showed lower *fbxo32* transcript levels than the NCM460 cell line (*p*\<0.05, [Figure 3](#f3-medscimonit-24-1080){ref-type="fig"}). Similarly, the SMAD4 and PAI-1 protein levels were lower in those CRC cell lines compared to the NCM460 cell line, and *vegf* also showed an opposite expression pattern ([Figure 3](#f3-medscimonit-24-1080){ref-type="fig"}).

Correlations of FBXO32 expression with survival of CRC
------------------------------------------------------

To further investigate the correlation of FBXO32 expression with the survival of CRC, Kaplan-Meier analyses were performed. As shown in ([Figure 4](#f4-medscimonit-24-1080){ref-type="fig"}), the 5-year overall survival of low-FBXO32 expression group was significantly shorter than that of high-FBXO32 expression group (*p*=0.010), indicating that down-regulation of FBXO32 might be correlated with poor survival of CRC.

Discussion
==========

Tumor metastasis and invasion consist of disruption of the basement membrane, stromal infiltration, extravasation and tumor cell invasion into a target organ. Our investigation of the TGF-β/Smad4 downstream target *fbxo32* further supports this hypothesis. *Fbxo32* is a downstream gene of *smad4*. Nuclear proteins are synthesized in the cytoplasm and need to be imported via the nuclear-pore complexes into the nucleus \[[@b14-medscimonit-24-1080]\]. As a key gene of the TGF-β/Smad4 pathway, *smad4* nuclear translocation may play a crucial role in regulating target gene expression \[[@b15-medscimonit-24-1080]\]. *Smad4* was originally isolated as a tumor suppressor gene on chromosome 18q21.1 in pancreatic ductal adenocarcinomas \[[@b13-medscimonit-24-1080]\]. Inactivation of *smad4* at the gene or protein level has been shown to be essential for the progression of several tumors \[[@b16-medscimonit-24-1080],[@b17-medscimonit-24-1080]\]. *Smad4* inactivation in cancers can be attributed to several factors, including homozygous deletion or loss of heterozygosity \[[@b12-medscimonit-24-1080],[@b18-medscimonit-24-1080]\], and further studies should be performed to elucidate the exact mechanism of *smad4* inactivation in CRC. The TGF-β signalling pathway is central in cell differentiation and stem cell maintenance \[[@b19-medscimonit-24-1080]\]. Disruption of the TGF-β signal transduction pathway has been observed in a significant subset of human cancers. In recent reports, disruption of TGF-β signalling was shown to promote the formation of cancer stem/progenitor cells in liver and breast cancer \[[@b20-medscimonit-24-1080],[@b21-medscimonit-24-1080]\]. Dysregulation of the TGF-β/Smad4 signalling pathway is a common event leading to loss of growth inhibition in CRC \[[@b22-medscimonit-24-1080]\]. However, the mechanism underlying this dysregulation is still unclear.

In our study, we used immunohistochemistry, qRT-PCR and Western blot analyses to test FBXO32 expression and found that FBXO32 levels were high in normal colorectal and low in CRC samples. *Fbxo32* expression was low in CRC, and it may be a tumor suppressor gene. Our results suggest that dysregulation of the TGF-β/Smad4 signalling pathway may contribute to *fbxo32* methylation in CRC. Promoter hypermethylation of *fbxo32* was observed in ovarian cancer cells showing constitutive *smad4* nuclear translocation \[[@b23-medscimonit-24-1080]\]. A previous study showed that the AKT signalling pathway negatively regulates *fbxo32*, which indicates that it may also be involved in regulating cell survival \[[@b24-medscimonit-24-1080]\]. However, the role of *smad4* in the methylation of *fbxo32* requires further investigation. The mechanism of *fbxo32* silencing in breast cancer cells may be different than that in CRC, and off-target effects of 5azaDC cannot be overlooked \[[@b7-medscimonit-24-1080]\]. Under conditions of long-term signal disruption, recruitment of repressive factors causes progressive accumulation of DNA methylation at the targeted promoter, which eventually establishes an epigenetic memory for the generation of an inactive heterochromatin state \[[@b25-medscimonit-24-1080]\]. Aberrant promoter methylation of TGFBR1 was reported to cause TGF-β resistance in gastric cancer, but when the selected CpG sites were different, the methylation frequency was also altered \[[@b26-medscimonit-24-1080],[@b27-medscimonit-24-1080]\]. Many studies have shown that multiple growth factors and their receptors, including the *vegf* system, play roles in tumor invasion and metastasis \[[@b28-medscimonit-24-1080]\], and the regulation of the *vegf* signalling axis has become a major focus of current research. *Smad4* restoration influenced angiogenesis by decreasing the expression of *vegf* \[[@b29-medscimonit-24-1080]\]. *Smad4* also inhibited the secretion of *vegf-a* and *vegf-c* to promote angiogenesis in tumors by autocrine or paracrine pathways, which may be a mechanism underlying inhibition of tumor growth \[[@b30-medscimonit-24-1080]\].

Overall, we believed that *fbxo32* is downregulated in CRC with impaired TGF-β/Smad4 signalling, and promoter hypermethylation may be one of the mechanisms for inactivation of *fbxo32* in CRC, particularly in CRC patients with an UGIC family history of North China \[[@b31-medscimonit-24-1080]\]. Additionally, decreased expression and hypermethylation of *fbxo32*, along with a positive UGIC family history and stage III and IV classification, are highly predictive of metastasis and poor prognosis in CRC. Further studies need to be performed to determine whether *fbxo32* can be used as a target to improve clinical outcomes of CRC. Above results support the hypothesis that aberrant TGF-β/Smad4 signalling can cause epigenetic silencing of its downstream target *fbxo32* in CRC. Plasminogen activator inhibitor-1 (*pai-1*) is a proteolytic factor that plays a role in invasion and metastatic diffusion by modulating extracellular matrix degradation, cell proliferation and adhesion, which is required for the invasive process, as observed during wound healing and cancer invasion \[[@b32-medscimonit-24-1080],[@b33-medscimonit-24-1080]\]. *Pai-1* has been suggested as a target for the development of antithrombotic agents and promotion of fibrinolysis \[[@b34-medscimonit-24-1080]\]. Furthermore, one of the major regulators of *pai-1* expression, TGF-β1, was increased in pre-malignant oral leukoplakia and in oral squamous cell carcinoma \[[@b35-medscimonit-24-1080],[@b36-medscimonit-24-1080]\].

Thus, *fbxo32* is epigenetically silenced in CRC cells with impaired TGF-β/Smad4 signalling and may be a new tumor suppressor in CRC. As high levels of *fbxo32* methylation predict survival in CRC patients, we hypothesized that *fbxo32* may act as a methylation biomarker for this disease.

There are 2 limitations in our study. First, due to the tumor samples are drawn from the specimen database, normal mucosa samples are obtained from volunteers, there were fewer normal mucosa samples than tumors. Our future study in this area will include more normal mucosa samples. Second, the study lacked information about relative levels of genes expression in CRC cases. In our next study, we will assess genes expression in CRC cases.

Conclusions
===========

We showed that FBXO32 was expressed in CRC and was negatively associated with the primary tumor stage and nuclear grade. Elevated expression of FBXO32 predicts a longer survival in CRC patients. Therefore, targeting *fbxo32* may be a potential strategy for the treatment of CRC due to its tumor suppressor function by the process of TGF-β. However, the in-depth mechanism requires further investigation.
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![Immunohistochemical staining for FBXO32 and SMAD4 in differentiated tissues (original magnification ×200). (**A, B**) FBXO32 staining in normal tissues; (**C, D**) FBXO32 staining in tumor tissues; (**E, F**) SMAD4 staining in normal tissues; (G, H) SMAD4 staining in tumor tissues.](medscimonit-24-1080-g001){#f1-medscimonit-24-1080}

![The *fbxo32*, *smad-4*, *pai-1* and*vegf* mRNA levels determine in cancer cell lines by qRT-PCR. (\* *p*\<0.05, \*\* *p*\<0.01, \*\*\* *p*\<0.001).](medscimonit-24-1080-g002){#f2-medscimonit-24-1080}

![Evaluation of FBXO32, SMAD-4, PAI-1 and VEGF protein levels in cancer cell lines by Western blot.](medscimonit-24-1080-g003){#f3-medscimonit-24-1080}

![Overall survival analysis according to the Kaplan-Meier method for FBXO32 expression (log-rank test, *p*=0.010).](medscimonit-24-1080-g004){#f4-medscimonit-24-1080}

###### 

Clinicopathological characteristics of patients with CRC (n=122).

  Characteristic                                Value         \%
  --------------------------------------------- ------------- -------
  Age median (range), years                     63 (21--85)   
  Gender                                                      
   Male                                         73            59.84
   Female                                       49            40.16
  Tumour Nodes Metastases category                            
   T1                                           2             1.64
   T2                                           11            9.02
   T3                                           108           88.52
   T4                                           1             0.82
   N0                                           72            59.02
   N1                                           34            27.87
   N2                                           16            13.11
   M0                                           121           99.18
   M1                                           1             0.82
  American Joint Committee on Cancer category                 
   I                                            8             6.55
   II                                           64            52.46
   III                                          49            40.16
   IV                                           1             0.82
  Differentiation                                             
   Low differentiation                          21            17.21
   Moderate differentiation                     97            79.51
   High differentiation                         4             3.28

Histology of all tumour specimens and regional lymph nodes was confirmed with haematoxylin--eosin staining according to the International Union against Cancer Tumour Nodes Metastases classification. Union for International Cancer Control released the eighth edition of the TNM staging of malignancies. AJCC is a classification system developed by the American Joint Committee on Cancer for describing the extent of disease progression in cancer patients.

###### 

Primers for real-time PCR.

  Gene                             Accession number   Primer sequence                  Product length (bp)
  -------------------------------- ------------------ -------------------------------- ---------------------
  FBXO32                           NM_017617.3        F: 5′-CCTTTGTGCTTCTGTTCTTCG-3′   212
  R: 5′-CCACTCATTCTGGTTGTCGTC-3′                                                       
  VEGF                             NM_003376.5        F: 5′-CGCAAGAAATCCCGGTATAA-3′    68
  R: 5′-AAATGCTTTCTCCGCTCTGA-3′                                                        
  Smad4                            NM_005359.5        F: 5′-GGTTGCACATAGGCAAAGGT-3′    122
  R: 5′-ACGCCCAGCTTCTCTGTCTA-3′                                                        
  PAI-1                            NM_033049.3        F: 5′-CACCCTCAGCATGTTCATTG-3′    571
  R: 5′-GGTCATGTTGCCTTTCCAGT-3′                                                        
  GAPDH                            NM_002046.4        F: 5′-AGGTCGGAGTCAACGGATTTG-3′   532
  R: 5′-GTGATGGCATGGACTGTGGT-3′                                                        

###### 

The expression of FBXO32 and SMAD4 with clinicopathological parameters in CRC.

  Variable                No. of patients   FBXO32 expression levels   *P* value   SMAD4 expression levels                                         *P* value        
  ----------------------- ----------------- -------------------------- ----------- --------------------------------------------------------------- ----------- ---- ---------------------------------------------------------------
  Age (years)                                                                                                                                                       
   \<50                   101               78                         23          **0.570**                                                       67          34   **0.697**
   ≥50                    21                15                         6                                                                           13          8    
  Gender                                                                                                                                                            **0.057**
   Male                   73                63                         10          **0.927**                                                       59          14   
   Female                 49                42                         7                                                                           32          17   
  Tumour stage                                                                     **0.016**[\*](#tfn3-medscimonit-24-1080){ref-type="table-fn"}                    **0.869**
   A--B                   79                79                         3                                                                           69          10   
   C--D                   43                36                         7                                                                           38          5    
  Grade                                                                            **0.012**[\*](#tfn3-medscimonit-24-1080){ref-type="table-fn"}                    **0.005**[\*](#tfn3-medscimonit-24-1080){ref-type="table-fn"}
   LMP                    21                11                         10                                                                          13          8    
   LG                     97                80                         17                                                                          85          12   
   G                      4                 3                          1                                                                           2           2    
  Lymph node metastasis                                                            **0.031**[\*](#tfn3-medscimonit-24-1080){ref-type="table-fn"}                    
   Negative               86                79                         7                                                                           77          9    **0.006**[\*](#tfn3-medscimonit-24-1080){ref-type="table-fn"}
   Positive               36                28                         8                                                                           25          11   

1\. Immunostaining grades observed using light microscopy. The criteria used for assessment were previously reported. 2. Pearson χ^2^ test for non-2×2 tables was used.

*P*\<0.05 was considered as statistically significant.
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